Otelixizumab

Drug Profile

Otelixizumab

Alternative Names: ChAglyCD3; GSK-2136525; Humanised anti-CD3 monoclonal antibody - Tolerx; TRX4; TRX4 antibody (anti-CD3)

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator BTG
  • Developer GlaxoSmithKline; Tolerx
  • Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Graves ophthalmopathy; Multiple sclerosis; Myasthenia gravis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 01 Mar 2014 Phase-II clinical trials in Type-1 diabetes mellitus (newly-diagnosed) in Belgium (IV)
  • 12 Feb 2014 Biomarkers information updated
  • 15 Nov 2013 GlaxoSmithKline terminates a phase I trial in Rheumatoid arthritis in Russia, Spain and the United Kingdom (NCT01077531)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top